Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$41.54M, compared with -$16.05M a year earlier. Trailing-twelve-month operating income was -$151.19M.
Context
- Operating income amounted to 959.1% of revenue in FY2025, down 395.2 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 2 analysts of -$89.85M (+28.5%) for the fiscal year ending Dec 2026, a step up from the +8.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$41.54M+14.0% QoQ
- Last fiscal yearDec 2025
- -$125.7M+8.0% YoY
- LTMMar 2026
- -$151.19M-108.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -158.7% | -72.2% | +86.5 pp |
| 1 year | +8.0% | +28.5% | +20.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (125.7M) USD
- Year-over-year change
- +8.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (125.7M) | +8.0% |
| FY2024 | 2024-12-31 | (136.7M) | -15.5% |
| FY2023 | 2023-12-31 | (118.38M) | -5.6% |
| FY2022 | 2022-12-31 | (112.09M) | -21.4% |
| FY2021 | 2021-12-31 | (92.31M) | — |
Operating Income vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -108.7% is the lowest of 10, against a peer median of -3.6%.
- Operating income amounts to 861.2% of revenue for TNXP, versus a peer median of 3669.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.58M USD | +17.4% | — | — |
| FY2025 | -€53.43M EUR | -3.6% | — | 1916.9% | |
| LTM Mar 2026 | -$65.46M USD | -25.5% | — | 3669.4% | |
| LTM Mar 2026 | -$76.97M USD | -71.3% | — | — | |
| LTM Mar 2026 | -$79.16M USD | -57.0% | — | 134164.4% | |
| LTM Mar 2026 | -$86.47M USD | -11.3% | — | — | |
| LTM Mar 2026 | -$87.64M USD | +23.2% | — | 7641.0% | |
| LTM Mar 2026 | -$116.31M USD | +11.9% | — | — | |
| LTM Mar 2026 | -$139.42M USD | +30.5% | — | 2207.5% | |
| LTM Mar 2026 | -$151.19M USD | -108.7% | — | 861.2% | |
| Peer median (excluding TNXP) | — | -3.6% | — | 3669.4% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.